5d9q › Citations

Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.

<div class='caption-title'>Antibody features frequency analysis.</div>
<div class='caption-title'>Limited somatic hypermutation of VRC01-like antibodies is sufficient to afford broad and potent neutralization.</div>
<div class='caption-title'>Polyspecificity analysis of MinVRC01 and Min12A21.</div>
Jardine JG, Sok D, Julien JP, Briney B, Sarkar A, Liang CH, Scherer EA, Henry Dunand CJ, Adachi Y, Diwanji D, Hsueh J, Jones M, Kalyuzhniy O, Kubitz M, Spencer S, Pauthner M, Saye-Francisco KL, Sesterhenn F, Wilson PC, Galloway DM, Stanfield RL, Wilson IA, Burton DR, Schief WR
OpenAccess logo PLoS Pathog 12 e1005815 (2016)
Cited: 79 times
EuropePMC logo PMID: 27560183

Abstract

An optimal HIV vaccine should induce broadly neutralizing antibodies (bnAbs) that neutralize diverse viral strains and subtypes. However, potent bnAbs develop in only a small fraction of HIV-infected individuals, all contain rare features such as extensive mutation, insertions, deletions, and/or long complementarity-determining regions, and some are polyreactive, casting doubt on whether bnAbs to HIV can be reliably induced by vaccination. We engineered two potent VRC01-class bnAbs that minimized rare features. According to a quantitative features frequency analysis, the set of features for one of these minimally mutated bnAbs compared favorably with all 68 HIV bnAbs analyzed and was similar to antibodies elicited by common vaccines. This same minimally mutated bnAb lacked polyreactivity in four different assays. We then divided the minimal mutations into spatial clusters and dissected the epitope components interacting with those clusters, by mutational and crystallographic analyses coupled with neutralization assays. Finally, by synthesizing available data, we developed a working-concept boosting strategy to select the mutation clusters in a logical order following a germline-targeting prime. We have thus developed potent HIV bnAbs that may be more tractable vaccine goals compared to existing bnAbs, and we have proposed a strategy to elicit them. This reductionist approach to vaccine design, guided by antibody and antigen structure, could be applied to design candidate vaccines for other HIV bnAbs or protective Abs against other pathogens.

Reviews - 5d9q mentioned but not cited (1)

  1. The HIV-1 envelope glycoprotein structure: nailing down a moving target. Ward AB, Wilson IA. Immunol Rev 275 21-32 (2017)

Articles - 5d9q mentioned but not cited (10)

  1. Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. Julien JP, Lee JH, Ozorowski G, Hua Y, Torrents de la Peña A, de Taeye SW, Nieusma T, Cupo A, Yasmeen A, Golabek M, Pugach P, Klasse PJ, Moore JP, Sanders RW, Ward AB, Wilson IA. Proc Natl Acad Sci U S A 112 11947-11952 (2015)
  2. Fitness landscape of the human immunodeficiency virus envelope protein that is targeted by antibodies. Louie RHY, Kaczorowski KJ, Barton JP, Chakraborty AK, McKay MR. Proc Natl Acad Sci U S A 115 E564-E573 (2018)
  3. Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer. Sarkar A, Bale S, Behrens AJ, Kumar S, Sharma SK, de Val N, Pallesen J, Irimia A, Diwanji DC, Stanfield RL, Ward AB, Crispin M, Wyatt RT, Wilson IA. Nat Commun 9 1956 (2018)
  4. Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements. Henderson R, Lu M, Zhou Y, Mu Z, Parks R, Han Q, Hsu AL, Carter E, Blanchard SC, Edwards RJ, Wiehe K, Saunders KO, Borgnia MJ, Bartesaghi A, Mothes W, Haynes BF, Acharya P, Munir Alam S. Nat Commun 11 520 (2020)
  5. Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. Schiffner T, Pallesen J, Russell RA, Dodd J, de Val N, LaBranche CC, Montefiori D, Tomaras GD, Shen X, Harris SL, Moghaddam AE, Kalyuzhniy O, Sanders RW, McCoy LE, Moore JP, Ward AB, Sattentau QJ. PLoS Pathog 14 e1006986 (2018)
  6. Structural basis of broad HIV neutralization by a vaccine-induced cow antibody. Stanfield RL, Berndsen ZT, Huang R, Sok D, Warner G, Torres JL, Burton DR, Ward AB, Ward AB, Wilson IA, Smider VV. Sci Adv 6 eaba0468 (2020)
  7. Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11. Moyo T, Ereño-Orbea J, Jacob RA, Pavillet CE, Kariuki SM, Tangie EN, Julien JP, Dorfman JR. J Virol 92 e02261-17 (2018)
  8. Estimation of the breadth of CD4bs targeting HIV antibodies by molecular modeling and machine learning. Conti S, Karplus M. PLoS Comput Biol 15 e1006954 (2019)
  9. Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use. Kadonosono T, Yimchuen W, Ota Y, See K, Furuta T, Shiozawa T, Kitazawa M, Goto Y, Patil A, Kuchimaru T, Kizaka-Kondoh S. Sci Rep 10 891 (2020)
  10. Design of immunogens to elicit broadly neutralizing antibodies against HIV targeting the CD4 binding site. Conti S, Kaczorowski KJ, Song G, Porter K, Andrabi R, Burton DR, Chakraborty AK, Karplus M. Proc Natl Acad Sci U S A 118 e2018338118 (2021)


Reviews citing this publication (18)

  1. Recent progress in broadly neutralizing antibodies to HIV. Sok D, Burton DR. Nat Immunol 19 1179-1188 (2018)
  2. Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem. Havenar-Daughton C, Lee JH, Crotty S. Immunol Rev 275 49-61 (2017)
  3. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. Landais E, Moore PL. Retrovirology 15 61 (2018)
  4. Factors in B cell competition and immunodominance. Abbott RK, Crotty S. Immunol Rev 296 120-131 (2020)
  5. When designing vaccines, consider the starting material: the human B cell repertoire. Havenar-Daughton C, Abbott RK, Schief WR, Crotty S. Curr Opin Immunol 53 209-216 (2018)
  6. Beyond Hot Spots: Biases in Antibody Somatic Hypermutation and Implications for Vaccine Design. Schramm CA, Douek DC. Front Immunol 9 1876 (2018)
  7. Assessing human B cell repertoire diversity and convergence. Imkeller K, Wardemann H. Immunol Rev 284 51-66 (2018)
  8. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Verkoczy L, Alt FW, Tian M. Immunol Rev 275 89-107 (2017)
  9. The Neutralizing Antibody Response to the HIV-1 Env Protein. Moore PL. Curr HIV Res 16 21-28 (2018)
  10. Recombinant subunit vaccines for soil-transmitted helminths. Noon JB, Aroian RV. Parasitology 144 1845-1870 (2017)
  11. Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. Kepler TB, Wiehe K. Immunol Rev 275 129-144 (2017)
  12. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses. Ringel O, Vieillard V, Debré P, Eichler J, Büning H, Dietrich U. Viruses 10 E197 (2018)
  13. Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem. Verkoczy L. Adv Immunol 134 235-352 (2017)
  14. Single-Cell Technologies Applied to HIV-1 Research: Reaching Maturity. Sannier G, Dubé M, Kaufmann DE. Front Microbiol 11 297 (2020)
  15. To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1. Griffith SA, McCoy LE. Front Immunol 12 708227 (2021)
  16. Env-Specific Antibodies in Chronic Infection versus in Vaccination. Soldemo M, Karlsson Hedestam GB. Front Immunol 8 1057 (2017)
  17. Immunological mechanisms of inducing HIV immunity in infants. Fouda GG, De Paris K, Levy O, Marchant A, Gray G, Permar S, Marovich M, Singh A. Vaccine 38 411-415 (2020)
  18. HIV-1 Envelope Conformation, Allostery, and Dynamics. Bennett AL, Henderson R. Viruses 13 852 (2021)

Articles citing this publication (50)

  1. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, Limbo O, Smith C, Song G, Woehl J, Yang L, Abbott RK, Callaghan S, Garcia E, Hurtado J, Parren M, Peng L, Ramirez S, Ricketts J, Ricciardi MJ, Rawlings SA, Wu NC, Yuan M, Smith DM, Nemazee D, Teijaro JR, Voss JE, Wilson IA, Andrabi R, Briney B, Landais E, Sok D, Jardine JG, Burton DR. Science 369 956-963 (2020)
  2. HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Steichen JM, Kulp DW, Tokatlian T, Escolano A, Dosenovic P, Stanfield RL, McCoy LE, Ozorowski G, Hu X, Kalyuzhniy O, Briney B, Schiffner T, Garces F, Freund NT, Gitlin AD, Menis S, Georgeson E, Kubitz M, Adachi Y, Jones M, Mutafyan AA, Yun DS, Mayer CT, Ward AB, Burton DR, Wilson IA, Irvine DJ, Nussenzweig MC, Schief WR. Immunity 45 483-496 (2016)
  3. A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. Kreye J, Reincke SM, Kornau HC, Sánchez-Sendin E, Corman VM, Liu H, Yuan M, Wu NC, Zhu X, Lee CD, Trimpert J, Höltje M, Dietert K, Stöffler L, von Wardenburg N, van Hoof S, Homeyer MA, Hoffmann J, Abdelgawad A, Gruber AD, Bertzbach LD, Vladimirova D, Li LY, Barthel PC, Skriner K, Hocke AC, Hippenstiel S, Witzenrath M, Suttorp N, Kurth F, Franke C, Endres M, Schmitz D, Jeworowski LM, Richter A, Schmidt ML, Schwarz T, Müller MA, Drosten C, Wendisch D, Sander LE, Osterrieder N, Wilson IA, Prüss H. Cell 183 1058-1069.e19 (2020)
  4. Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. Abbott RK, Lee JH, Menis S, Skog P, Rossi M, Ota T, Kulp DW, Bhullar D, Kalyuzhniy O, Havenar-Daughton C, Schief WR, Nemazee D, Crotty S. Immunity 48 133-146.e6 (2018)
  5. A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Steichen JM, Lin YC, Havenar-Daughton C, Pecetta S, Ozorowski G, Willis JR, Toy L, Sok D, Liguori A, Kratochvil S, Torres JL, Kalyuzhniy O, Melzi E, Kulp DW, Raemisch S, Hu X, Bernard SM, Georgeson E, Phelps N, Adachi Y, Kubitz M, Landais E, Umotoy J, Robinson A, Briney B, Wilson IA, Burton DR, Ward AB, Crotty S, Batista FD, Schief WR. Science 366 eaax4380 (2019)
  6. Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. Sok D, Le KM, Vadnais M, Saye-Francisco KL, Jardine JG, Torres JL, Berndsen ZT, Kong L, Stanfield R, Ruiz J, Ramos A, Liang CH, Chen PL, Criscitiello MF, Mwangi W, Wilson IA, Ward AB, Smider VV, Burton DR. Nature 548 108-111 (2017)
  7. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Sok D, Briney B, Jardine JG, Kulp DW, Menis S, Pauthner M, Wood A, Lee EC, Le KM, Jones M, Ramos A, Kalyuzhniy O, Adachi Y, Kubitz M, MacPherson S, Bradley A, Friedrich GA, Schief WR, Burton DR. Science 353 1557-1560 (2016)
  8. Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. Duan H, Chen X, Boyington JC, Cheng C, Zhang Y, Jafari AJ, Stephens T, Tsybovsky Y, Kalyuzhniy O, Zhao P, Menis S, Nason MC, Normandin E, Mukhamedova M, DeKosky BJ, Wells L, Schief WR, Tian M, Alt FW, Kwong PD, Mascola JR. Immunity 49 301-311.e5 (2018)
  9. Structure and Immune Recognition of the HIV Glycan Shield. Crispin M, Ward AB, Wilson IA. Annu Rev Biophys 47 499-523 (2018)
  10. The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. Havenar-Daughton C, Sarkar A, Kulp DW, Toy L, Hu X, Deresa I, Kalyuzhniy O, Kaushik K, Upadhyay AA, Menis S, Landais E, Cao L, Diedrich JK, Kumar S, Schiffner T, Reiss SM, Seumois G, Yates JR, Paulson JC, Bosinger SE, Wilson IA, Schief WR, Crotty S. Sci Transl Med 10 eaat0381 (2018)
  11. Molecular basis of human CD22 function and therapeutic targeting. Ereño-Orbea J, Sicard T, Cui H, Mazhab-Jafari MT, Benlekbir S, Guarné A, Rubinstein JL, Julien JP. Nat Commun 8 764 (2017)
  12. Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. Chuang GY, Geng H, Pancera M, Xu K, Cheng C, Acharya P, Chambers M, Druz A, Tsybovsky Y, Wanninger TG, Yang Y, Doria-Rose NA, Georgiev IS, Gorman J, Joyce MG, O'Dell S, Zhou T, McDermott AB, Mascola JR, Kwong PD. J Virol 91 e02268-16 (2017)
  13. Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. Wiehe K, Bradley T, Meyerhoff RR, Hart C, Williams WB, Easterhoff D, Faison WJ, Kepler TB, Saunders KO, Alam SM, Bonsignori M, Haynes BF. Cell Host Microbe 23 759-765.e6 (2018)
  14. cAb-Rep: A Database of Curated Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody Prevalence. Guo Y, Chen K, Kwong PD, Shapiro L, Sheng Z. Front Immunol 10 2365 (2019)
  15. Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan. Umotoy J, Bagaya BS, Joyce C, Schiffner T, Menis S, Saye-Francisco KL, Biddle T, Mohan S, Vollbrecht T, Kalyuzhniy O, Madzorera S, Kitchin D, Lambson B, Nonyane M, Kilembe W, IAVI Protocol C Investigators, IAVI African HIV Research Network, Poignard P, Schief WR, Burton DR, Murrell B, Moore PL, Briney B, Sok D, Landais E. Immunity 51 141-154.e6 (2019)
  16. Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. Bonsignori M, Scott E, Wiehe K, Easterhoff D, Alam SM, Hwang KK, Cooper M, Xia SM, Zhang R, Montefiori DC, Henderson R, Nie X, Kelsoe G, Moody MA, Chen X, Joyce MG, Kwong PD, Connors M, Mascola JR, McGuire AT, Stamatatos L, Medina-Ramírez M, Sanders RW, Saunders KO, Kepler TB, Haynes BF. Immunity 49 1162-1174.e8 (2018)
  17. Rapid Germinal Center and Antibody Responses in Non-human Primates after a Single Nanoparticle Vaccine Immunization. Havenar-Daughton C, Carnathan DG, Boopathy AV, Upadhyay AA, Murrell B, Reiss SM, Enemuo CA, Gebru EH, Choe Y, Dhadvai P, Viviano F, Kaushik K, Bhiman JN, Briney B, Burton DR, Bosinger SE, Schief WR, Irvine DJ, Silvestri G, Crotty S. Cell Rep 29 1756-1766.e8 (2019)
  18. B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. Huang D, Abbott RK, Havenar-Daughton C, Skog PD, Al-Kolla R, Groschel B, Blane TR, Menis S, Tran JT, Thinnes TC, Volpi SA, Liguori A, Schiffner T, Villegas SM, Kalyuzhniy O, Pintea M, Voss JE, Phelps N, Tingle R, Rodriguez AR, Martin G, Kupryianov S, deCamp A, Schief WR, Nemazee D, Crotty S. Proc Natl Acad Sci U S A 117 22920-22931 (2020)
  19. Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity. Prigent J, Jarossay A, Planchais C, Eden C, Dufloo J, Kök A, Lorin V, Vratskikh O, Couderc T, Bruel T, Schwartz O, Seaman MS, Ohlenschläger O, Dimitrov JD, Mouquet H. Cell Rep 23 2568-2581 (2018)
  20. Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core. Borst AJ, Weidle CE, Gray MD, Frenz B, Snijder J, Joyce MG, Georgiev IS, Stewart-Jones GB, Kwong PD, McGuire AT, DiMaio F, Stamatatos L, Pancera M, Veesler D. Elife 7 e37688 (2018)
  21. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. Chen X, Zhou T, Schmidt SD, Duan H, Cheng C, Chuang GY, Gu Y, Louder MK, Lin BC, Shen CH, Sheng Z, Zheng MX, Doria-Rose NA, Joyce MG, Shapiro L, Tian M, Alt FW, Kwong PD, Mascola JR. Immunity 54 324-339.e8 (2021)
  22. Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. Hwang JK, Wang C, Du Z, Meyers RM, Kepler TB, Neuberg D, Kwong PD, Mascola JR, Joyce MG, Bonsignori M, Haynes BF, Yeap LS, Alt FW. Proc Natl Acad Sci U S A 114 8614-8619 (2017)
  23. Conformational Heterogeneity of the HIV Envelope Glycan Shield. Yang M, Huang J, Simon R, Wang LX, MacKerell AD. Sci Rep 7 4435 (2017)
  24. Porcine reproductive and respiratory syndrome virus neutralizing antibodies provide in vivo cross-protection to PRRSV1 and PRRSV2 viral challenge. Robinson SR, Rahe MC, Gray DK, Martins KV, Murtaugh MP. Virus Res 248 13-23 (2018)
  25. Chronic Viral Infection Promotes Efficient Germinal Center B Cell Responses. Fallet B, Hao Y, Florova M, Cornille K, de Los Aires AV, Girelli Zubani G, Ertuna YI, Greiff V, Menzel U, Hammad K, Merkler D, Reddy ST, Weill JC, Reynaud CA, Pinschewer DD. Cell Rep 30 1013-1026.e7 (2020)
  26. Multiplexed CRISPR/CAS9-mediated engineering of pre-clinical mouse models bearing native human B cell receptors. Wang X, Ray R, Kratochvil S, Melzi E, Lin YC, Giguere S, Xu L, Warner J, Cheon D, Liguori A, Groschel B, Phelps N, Adachi Y, Tingle R, Wu L, Crotty S, Kirsch KH, Nair U, Schief WR, Batista FD. EMBO J 40 e105926 (2021)
  27. Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies. Otsuka Y, Schmitt K, Quinlan BD, Gardner MR, Alfant B, Reich A, Farzan M, Choe H. PLoS Pathog 14 e1007238 (2018)
  28. Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer. He L, Lin X, de Val N, Saye-Francisco KL, Mann CJ, Augst R, Morris CD, Azadnia P, Zhou B, Sok D, Ozorowski G, Ward AB, Burton DR, Zhu J. Front Immunol 8 1025 (2017)
  29. Identifying immunologically-vulnerable regions of the HCV E2 glycoprotein and broadly neutralizing antibodies that target them. Quadeer AA, Louie RHY, McKay MR. Nat Commun 10 2073 (2019)
  30. Antibodies to a Citrullinated Porphyromonas gingivalis Epitope Are Increased in Early Rheumatoid Arthritis, and Can Be Produced by Gingival Tissue B Cells: Implications for a Bacterial Origin in RA Etiology. Sherina N, de Vries C, Kharlamova N, Sippl N, Jiang X, Brynedal B, Kindstedt E, Hansson M, Mathsson-Alm L, Israelsson L, Stålesen R, Saevarsdottir S, Holmdahl R, Hensvold A, Johannsen G, Eriksson K, Sallusto F, Catrina AI, Rönnelid J, Grönwall C, Yucel-Lindberg T, Alfredsson L, Klareskog L, Piccoli L, Malmström V, Amara K, Lundberg K. Front Immunol 13 804822 (2022)
  31. Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans. Wu NR, Nicely NI, Lee EM, Reed RK, Watts BE, Cai F, Walkowicz WE, Aussedat B, Jones JA, Eaton A, Trama AM, Alam SM, Montefiori DC, Haynes BF, Saunders KO. PLoS Pathog 15 e1008165 (2019)
  32. Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations. Swanson O, Rhodes B, Wang A, Xia SM, Parks R, Chen H, Sanzone A, Cooper M, Louder MK, Lin BC, Doria-Rose NA, Bonsignori M, Saunders KO, Wiehe K, Haynes BF, Azoitei ML. Cell Rep 36 109561 (2021)
  33. A naturally arising broad and potent CD4-binding site antibody with low somatic mutation. Barnes CO, Schoofs T, Gnanapragasam PNP, Golijanin J, Huey-Tubman KE, Gruell H, Schommers P, Suh-Toma N, Lee YE, Cetrulo Lorenzi JC, Piechocka-Trocha A, Scheid JF, West AP, Walker BD, Seaman MS, Klein F, Nussenzweig MC, Bjorkman PJ. Sci Adv 8 eabp8155 (2022)
  34. Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice. Melzi E, Willis JR, Ma KM, Lin YC, Kratochvil S, Berndsen ZT, Landais EA, Kalyuzhniy O, Nair U, Warner J, Steichen JM, Kalyuzhniy A, Le A, Pecetta S, Perez M, Kirsch K, Weldon SR, Falcone S, Himansu S, Carfi A, Sok D, Ward AB, Schief WR, Batista FD. Immunity 55 2168-2186.e6 (2022)
  35. The Effects of Framework Mutations at the Variable Domain Interface on Antibody Affinity Maturation in an HIV-1 Broadly Neutralizing Antibody Lineage. Zhou JO, Zaidi HA, Ton T, Fera D. Front Immunol 11 1529 (2020)
  36. Efficient isolation of rare B cells using next-generation antigen barcoding. Hurtado J, Flynn C, Lee JH, Salcedo EC, Cottrell CA, Skog PD, Burton DR, Nemazee D, Schief WR, Landais E, Sok D, Briney B. Front Cell Infect Microbiol 12 962945 (2022)
  37. Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors. Virnik K, Nesti E, Dail C, Hockenbury M, Ni Y, Felber BK, Schief WR, Berkower I. Vaccine 35 3272-3278 (2017)
  38. HIV-1 CD4-binding site germline antibody-Env structures inform vaccine design. Dam KA, Barnes CO, Gristick HB, Schoofs T, Gnanapragasam PNP, Nussenzweig MC, Bjorkman PJ. Nat Commun 13 6123 (2022)
  39. Humanized V(D)J-rearranging and TdT-expressing mouse vaccine models with physiological HIV-1 broadly neutralizing antibody precursors. Luo S, Jing C, Ye AY, Kratochvil S, Cottrell CA, Koo JH, Chapdelaine Williams A, Francisco LV, Batra H, Lamperti E, Kalyuzhniy O, Zhang Y, Barbieri A, Manis JP, Haynes BF, Schief WR, Batista FD, Tian M, Alt FW. Proc Natl Acad Sci U S A 120 e2217883120 (2023)
  40. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies. Fetzer I, Davis-Gardner ME, Gardner MR, Alfant B, Weber JA, Prasad NR, Zhou AS, Farzan M. J Virol 93 e01653-18 (2019)
  41. Published Erratum Correction: Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. Jardine JG, Sok D, Julien JP, Briney B, Sarkar A, Liang CH, Scherer EM, Henry Dunand CJ, Adachi Y, Diwanji D, Hsueh J, Jones M, Kalyuzhniy O, Kubitz M, Spencer S, Pauthner M, Saye-Francisco KL, Sesterhenn F, Wilson PC, Galloway DA, Stanfield RL, Wilson IA, Burton DR, Schief WR. PLoS Pathog 12 e1005905 (2016)
  42. Germline-Encoded Positional Cysteine Polymorphisms Enhance Diversity in Antibody Ultralong CDR H3 Regions. Jenkins GW, Safonova Y, Smider VV. J Immunol 209 2141-2148 (2022)
  43. Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions. Caniels TG, Medina-Ramírez M, Zhang J, Sarkar A, Kumar S, LaBranche A, Derking R, Allen JD, Snitselaar JL, Capella-Pujol J, Sánchez IDM, Yasmeen A, Diaz M, Aldon Y, Bijl TPL, Venkatayogi S, Martin Beem JS, Newman A, Jiang C, Lee WH, Pater M, Burger JA, van Breemen MJ, de Taeye SW, Rantalainen K, LaBranche C, Saunders KO, Montefiori D, Ozorowski G, Ward AB, Crispin M, Moore JP, Klasse PJ, Haynes BF, Wilson IA, Wiehe K, Verkoczy L, Sanders RW. Cell Rep Med 4 101003 (2023)
  44. Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer. Lee JH, Nakao C, Appel M, Le A, Landais E, Kalyuzhniy O, Hu X, Liguori A, Mullen TM, Groschel B, Abbott RK, Sok D, Schief WR, Crotty S. Cell Rep 38 110485 (2022)
  45. Partial HIV C2V3 envelope sequence analysis reveals association of coreceptor tropism, envelope glycosylation and viral genotypic variability among Kenyan patients on HAART. Kitawi RC, Hunja CW, Aman R, Ogutu BR, Muigai AW, Kokwaro GO, Ochieng W. Virol J 14 29 (2017)
  46. Vaccine-elicited CD4 T cells prevent the deletion of antiviral B cells in chronic infection. Narr K, Ertuna YI, Fallet B, Cornille K, Dimitrova M, Marx AF, Martin K, Abreu Mota T, Künzli M, Schreiner D, Brunner TM, Kreutzfeldt M, Wagner I, Geier F, Bestmann L, Löhning M, Merkler D, King CG, Pinschewer DD. Proc Natl Acad Sci U S A 118 e2108157118 (2021)
  47. Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein. Xiang J, Su J, Lan Q, Zhao W, Zhou Y, Xu Y, Niu J, Xia S, Qi Q, Sidhu S, Lu L, Miersch S, Yang B. Commun Biol 5 1179 (2022)
  48. Assessing immunogenicity barriers of the HIV-1 envelope trimer. Maliqi L, Friedrich N, Glögl M, Schmutz S, Schmidt D, Rusert P, Schanz M, Zaheri M, Pasin C, Niklaus C, Foulkes C, Reinberg T, Dreier B, Abela I, Peterhoff D, Hauser A, Kouyos RD, Günthard HF, van Gils MJ, Sanders RW, Wagner R, Plückthun A, Trkola A. NPJ Vaccines 8 148 (2023)
  49. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage. Sacks D, Wiehe K, Morris L, Moore PL. J Virol 96 e0027022 (2022)
  50. HCV E1 influences the fitness landscape of E2 and may enhance escape from E2-specific antibodies. Zhang H, Bull RA, Quadeer AA, McKay MR. Virus Evol 9 vead068 (2023)


Quick links